| Assessment Status |
Awaiting response from Applicant |
| HTA ID |
22006 |
| Drug |
Pembrolizumab |
| Brand |
Keytruda® |
| Indication |
In combination with lenvatinib (Lenvima®) is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting, and who are not candidates for curative surgery or radiation. |
| Rapid review commissioned |
07/02/2022 |
| Rapid review completed |
04/03/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab in combination with lenvatinib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
01/04/2022 |
| Pre-submission consultation with Applicant |
09/05/2022 |
| Full submission received from Applicant |
21/02/2023 |
| Preliminary review sent to Applicant |
03/08/2023 |
| NCPE assessment re-commenced |
05/09/2023 |
| Follow-up to preliminary review sent to Applicant |
19/09/2023 |
